Novel BTK Inhibitor and Potential Targets in T-cell and Firmas

This chapter explores the potential of Pintra butyrutinib, a novel BTK inhibitor, in treating patients who have failed irreversible BTK inhibitors. It discusses ongoing trials comparing Pintra butyrutinib to chemotherapy and earlier generations of BTK inhibitors, as well as potential targets and combination approaches.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app